NURIX THERAPEUTICS INC (NRIX) Forecast, Price Target & Analyst Ratings
NASDAQ:NRIX • US67080M1036
15.1 USD
-0.12 (-0.79%)
At close: Mar 6, 2026
14.75 USD
-0.35 (-2.32%)
Pre-Market: 3/9/2026, 7:16:43 AM
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for NURIX THERAPEUTICS INC (NRIX).
Forecast Snapshot
Consensus Price Target
$30.60
+ 102.65% Upside
Next Earnings Forecast
Release DateApr 6, 2026
PeriodQ1 / 2026
EPS Estimate-$0.77
Revenue Estimate15.992M
ChartMill Buy Consensus
86.09%
Weighted Analyst Rating Score
Price Target Details & History
Consensus Price Target and Range
Mean target
$30.60
Upside
+ 102.65%
From current price of $15.10 to mean target of $30.60, Based on 23 analyst forecasts
Low
$22.22
Median
$30.60
High
$43.05
Price Target Revisions
1 Month
0.00%
3 Months
10.39%
Price Target Summary
23 analysts have analysed NRIX and the average price target is 30.6 USD. This implies a price increase of 102.65% is expected in the next year compared to the current price of 15.1.
The average price target has been revised upward by 10.39% in the past 3 months.
Analyst Ratings & History
Current Analyst Ratings
Analyst Ratings History
Analyst Ratings Consensus
ChartMill Buy Consensus
86.09%
NRIX was analyzed by 23 analysts. The buy percentage consensus is at 86. So analysts seem to be very confident about NRIX.
In the previous month the buy percentage consensus was at a similar level.
NRIX was analyzed by 23 analysts, which is quite many. So the average rating should be quite meaningful.
Recent Upgrades & Downgrades
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2026-01-29 | BTIG | Reiterate | Buy -> Buy |
| 2026-01-29 | Needham | Reiterate | Buy -> Buy |
| 2026-01-29 | RBC Capital | Maintains | Outperform -> Outperform |
| 2026-01-29 | Stifel | Maintains | Buy -> Buy |
| 2026-01-29 | Wells Fargo | Maintains | Overweight -> Overweight |
| 2026-01-29 | Piper Sandler | Maintains | Overweight -> Overweight |
| 2026-01-29 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2026-01-08 | Morgan Stanley | Upgrade | Equal-Weight -> Overweight |
| 2025-12-16 | Wells Fargo | Maintains | Overweight -> Overweight |
| 2025-12-10 | Mizuho | Maintains | Outperform -> Outperform |
| 2025-12-10 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2025-12-09 | BTIG | Maintains | Buy -> Buy |
| 2025-12-08 | Needham | Reiterate | Buy -> Buy |
| 2025-11-04 | BTIG | Reiterate | Buy -> Buy |
| 2025-11-04 | Needham | Reiterate | Buy -> Buy |
| 2025-10-27 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2025-10-23 | BTIG | Maintains | Buy -> Buy |
| 2025-10-23 | Wells Fargo | Maintains | Overweight -> Overweight |
| 2025-10-22 | Needham | Maintains | Buy -> Buy |
| 2025-10-21 | Mizuho | Initiate | Outperform |
| 2025-10-20 | Needham | Reiterate | Buy -> Buy |
| 2025-10-20 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-10-14 | Morgan Stanley | Maintains | Equal-Weight -> Equal-Weight |
| 2025-10-14 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2025-10-10 | Oppenheimer | Maintains | Outperform -> Outperform |
Next Earnings Forecast Details
Next Earnings Details
Release DateApr 6, 2026
PeriodQ1 / 2026
EPS Estimate-$0.77
Revenue Estimate15.992M
Revenue Q2Q-13.34%
EPS Q2Q-14.83%
Number of Analysts16
Next Earnings Revisions
Revenue (1 Month)
-1.74%
Revenue (3 Months)
-5.80%
EPS (1 Month)
2.53%
EPS (3 Months)
10.47%
Next Earnings Summary
NRIX is expected to report earnings on 4/6/2026. The consensus EPS estimate for the next earnings is -0.77 USD and the consensus revenue estimate is 15.99M USD.
The next earnings revenue estimate has been revised downward by 5.8% in the past 3 months. Downward revisions are a negative sign and indicate that analysts are more pessimistic about the next earnings compared to 3 months ago.
Full Analyst Estimates
Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates
| 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 76.987M 99.29% | 54.549M -29.15% | 83.98M 53.95% | 63.729M -24.11% | 80.505M 26.32% | 140.31M 74.29% | 246.5M 75.68% | 502.52M 103.86% | 843.67M 67.89% | 1.232B 46.03% | 1.621B 31.57% | |
| EBITDA YoY % growth | -147.53M 17.36% | -203.709M -38.08% | -276.926M -35.94% | -355.963M -28.54% | -388.719M -9.20% | -303.363M 21.96% | N/A | N/A | N/A | N/A | N/A | |
| EBIT YoY % growth | -155.063M 15.67% | -213.027M -37.38% | -285.666M -34.10% | -358.186M -25.39% | -381.779M -6.59% | -342.181M 10.37% | -294.937M 13.81% | -66.556M 77.43% | 230.17M 445.83% | 645.61M 180.49% | 1.004B 55.51% | |
| Operating Margin | -201.41% | -390.52% | -340.16% | -562.04% | -474.23% | -243.87% | -119.65% | -13.24% | 27.28% | 52.40% | 61.94% | |
| EPS YoY % growth | -2.65 28.95% | -2.89 -9.06% | -3.04 -5.19% | -3.11 -2.29% | -2.99 3.97% | -2.43 18.71% | -1.86 23.46% | -0.02 98.81% | 2.24 10,238.25% | 4.50 100.34% | 6.69 48.78% |
All data in USD
Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates
| Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | |
|---|---|---|---|---|
| EPS Q2Q % growth | -0.77 -14.83% | -0.78 -49.50% | -0.89 13.60% | -0.87 -6.51% |
| Revenue Q2Q % growth | 15.992M -13.34% | 18.632M -57.71% | 15.817M 100.37% | 16.925M 24.66% |
| EBITDA Q2Q % growth | -86.307M -42.62% | -91.397M -109.00% | N/A | N/A |
| EBIT Q2Q % growth | -86.565M -37.70% | -87.174M -80.40% | -92.819M -1.57% | -93.835M -12.92% |
All data in USD
Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data
Long Term Forward Growth Forecast Summary
Long Term EPS Growth (CAGR)
EPS Next 3 Year
6.31%
EPS Next 5 Year
14.79%
Long Term Revenue Growth (CAGR)
Revenue Next 3 Year
17.29%
Revenue Next 5 Year
42.03%
Long Term EBIT Growth (CAGR)
EBIT Next 3 Year
-1.20%
EBIT Next 5 Year
N/A
NURIX THERAPEUTICS INC / NRIX Forecast FAQ
What is the average price target for NURIX THERAPEUTICS INC (NRIX) stock?
23 analysts have analysed NRIX and the average price target is 30.6 USD. This implies a price increase of 102.65% is expected in the next year compared to the current price of 15.1.
When does NURIX THERAPEUTICS INC (NRIX) report earnings?
NURIX THERAPEUTICS INC (NRIX) will report earnings on 2026-04-06.
What are the consensus estimates for NRIX stock next earnings?
The consensus EPS estimate for the next earnings of NURIX THERAPEUTICS INC (NRIX) is -0.77 USD and the consensus revenue estimate is 15.99M USD.
How do analysts rate NURIX THERAPEUTICS INC (NRIX)?
The consensus rating for NURIX THERAPEUTICS INC (NRIX) is 86.087 / 100 . This indicates that analysts generally have a positive outlook on the stock.